These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 9756584)

  • 1. Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: post hoc analysis of ECASS I.
    Hacke W; Bluhmki E; Steiner T; Tatlisumak T; Mahagne MH; Sacchetti ML; Meier D
    Stroke; 1998 Oct; 29(10):2073-5. PubMed ID: 9756584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study.
    Steiner T; Bluhmki E; Kaste M; Toni D; Trouillas P; von Kummer R; Hacke W
    Cerebrovasc Dis; 1998; 8(4):198-203. PubMed ID: 9684058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials.
    Savitz SI; Lew R; Bluhmki E; Hacke W; Fisher M
    Stroke; 2007 Dec; 38(12):3205-12. PubMed ID: 17975102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS).
    Hacke W; Kaste M; Fieschi C; Toni D; Lesaffre E; von Kummer R; Boysen G; Bluhmki E; Höxter G; Mahagne MH
    JAMA; 1995 Oct; 274(13):1017-25. PubMed ID: 7563451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the National Institutes of Health Stroke Scale with disability outcome measures in acute stroke trials.
    Young FB; Weir CJ; Lees KR;
    Stroke; 2005 Oct; 36(10):2187-92. PubMed ID: 16179579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seven-day NIHSS is a sensitive outcome measure for exploratory clinical trials in acute stroke: evidence from the Virtual International Stroke Trials Archive.
    Kerr DM; Fulton RL; Lees KR;
    Stroke; 2012 May; 43(5):1401-3. PubMed ID: 22308254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the National Institute of Neurological Disorders and Stroke tissue plasminogen activator studies following European Cooperative Acute Stroke Study III patient selection criteria.
    Hemmen TM; Rapp KS; Emond JA; Raman R; Lyden PD
    J Stroke Cerebrovasc Dis; 2010; 19(4):290-3. PubMed ID: 20471855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators.
    Clark WM; Albers GW; Madden KP; Hamilton S
    Stroke; 2000 Apr; 31(4):811-6. PubMed ID: 10753980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated-measures analysis of the National Institute of Neurological Disorders and Stroke rt-PA stroke trial.
    Feng W; Vasquez G; Suri MF; Lakshminarayan K; Qureshi AI
    J Stroke Cerebrovasc Dis; 2011; 20(3):241-6. PubMed ID: 20621509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances.
    Alper BS; Foster G; Thabane L; Rae-Grant A; Malone-Moses M; Manheimer E
    BMJ Evid Based Med; 2020 Oct; 25(5):168-171. PubMed ID: 32430395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.
    Bluhmki E; Chamorro A; Dávalos A; Machnig T; Sauce C; Wahlgren N; Wardlaw J; Hacke W
    Lancet Neurol; 2009 Dec; 8(12):1095-102. PubMed ID: 19850525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombolytic therapy within 3 to 6 hours after onset of ischemic stroke: useful or harmful?
    Ringleb PA; Schellinger PD; Schranz C; Hacke W
    Stroke; 2002 May; 33(5):1437-41. PubMed ID: 11988629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial.
    Broderick JP; Lu M; Kothari R; Levine SR; Lyden PD; Haley EC; Brott TG; Grotta J; Tilley BC; Marler JR; Frankel M
    Stroke; 2000 Oct; 31(10):2335-41. PubMed ID: 11022060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial.
    Tilley BC; Marler J; Geller NL; Lu M; Legler J; Brott T; Lyden P; Grotta J
    Stroke; 1996 Nov; 27(11):2136-42. PubMed ID: 8898828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits ECASS-4: ExTEND.
    Amiri H; Bluhmki E; Bendszus M; Eschenfelder CC; Donnan GA; Leys D; Molina C; Ringleb PA; Schellinger PD; Schwab S; Toni D; Wahlgren N; Hacke W
    Int J Stroke; 2016 Feb; 11(2):260-7. PubMed ID: 26783318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis.
    Strbian D; Sairanen T; Meretoja A; Pitkäniemi J; Putaala J; Salonen O; Silvennoinen H; Kaste M; Tatlisumak T;
    Neurology; 2011 Jul; 77(4):341-8. PubMed ID: 21715707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
    Flint AC; Gupta R; Smith WS; Kamel H; Faigeles BS; Cullen SP; Rao VA; Bath PM; Wahlgren N; Ahmed N; Donnan GA;
    Int J Stroke; 2014 Aug; 9(6):705-10. PubMed ID: 25042855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Confirmation of tPA treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-tPA stroke trials.
    Saver JL; Yafeh B
    Stroke; 2007 Feb; 38(2):414-6. PubMed ID: 17234987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early neurologic improvement based on the National Institutes of Health Stroke Scale score predicts favorable outcome within 30 minutes after undergoing intravenous recombinant tissue plasminogen activator therapy.
    Takagi T; Kato T; Sakai H; Nishimura Y
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):69-74. PubMed ID: 23164483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1).
    Lampl Y; Zivin JA; Fisher M; Lew R; Welin L; Dahlof B; Borenstein P; Andersson B; Perez J; Caparo C; Ilic S; Oron U
    Stroke; 2007 Jun; 38(6):1843-9. PubMed ID: 17463313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.